Editas medicine stock price.

Our information suggests that Editas Medicine, Inc. insiders own under 1% of the company. It appears that the board holds about US$2.6m worth of stock. This compares to a market capitalization of ...Editas Medicine, Inc. (EDIT.NASDAQ) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Editas Medicine, Inc. | Nasdaq: EDIT | Nasdaq …Dec 1, 2023 · According to the issued ratings of 12 analysts in the last year, the consensus rating for Editas Medicine stock is Hold based on the current 1 sell rating, 6 hold ratings and 5 buy ratings for EDIT. The average twelve-month price prediction for Editas Medicine is $13.92 with a high price target of $30.00 and a low price target of $7.00. Learn ... Editas Medicine Inc Stock Price History. Editas Medicine Inc’s price is currently down 13.39% so far this month. During the month of March, Editas Medicine Inc’s stock price has reached a high of $9.18 and a low of $7.48. Over the last year, Editas Medicine Inc has hit prices as high as $21.60 and as low as $7.71. Year to date, Editas ...

Track Editas Medicine Inc (EDIT) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors

Get the latest Editas Medicine, Inc. (EDIT) stock news and headlines to help you in your trading and investing decisions.Complete Editas Medicine Inc. stock information by Barron's. View real-time EDIT stock price and news, along with industry-best analysis.

In the last 3 months, 6 analysts have offered 12-month price targets for Editas Medicine. The company has an average price target of $14.67 with a high of $22.00 and a low of $8.00.CAMBRIDGE, Mass., June 14, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it intends to offer and sell $125 million of shares of its common stock in an underwritten public offering. Editas Medicine intends to grant the underwriters a 30-day option to …Editas Medicine is a gene-editing technology company. Editas Medicine has lost over 60% of its value. Check out why I'm neutral on EDIT stock here.Jun 6, 2021 · For Editas Medicine stock forecast for 2031, 12 predictions are offered for each month of 2031 with average Editas Medicine stock forecast of $8.2, a high forecast of $8.21, and a low forecast of $8.19. The average Editas Medicine stock forecast 2031 represents a 4.21% increase from the last price of $7.86999988555908. Select an options expiration date from the drop-down list at the top of the table, and select "Near-the-Money" or "Show All' to view all options. Note: Option ...

Shares of Editas Medicine ( EDIT -0.26%) were down as much as 21% at one point on Thursday. The stock closed at $12.25 on Wednesday and opened at only $9.90 on Thursday, falling to as low as $9.61 ...

Gene editing stocks rallied Thursday as Wall Street took notice of the underperforming subsector issuing a series of bullish views despite recent selloff. Read more here.

In the last 3 months, 18 analysts have offered 12-month price targets for Editas Medicine. The company has an average price target of $19.17 with a high of $43.00 and a low of $6.00.Why Editas Medicine's Shares Jumped This Week. (Motley Fool) Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, …Understanding stock price lookup is a basic yet essential requirement for any serious investor. Whether you are investing for the long term or making short-term trades, stock price data gives you an idea what is going on in the markets.13 Okt 2023 ... Today's Editas Medicine Inc. Share Price - Explore EDIT stock Information, latest price chart, peers growth, market trend and start ...EDIT Editas Medicine Inc. 10.57 -0.15 ( -1.40%) Market Closed Delayed Prices By NASDAQ, in USD. Trade. Overview Chart Analysis News Stats.Editas Medicine, Inc. analysts consensus, targets, ratings and recommendations | Nasdaq: EDIT | Nasdaq ... RBC Capital Adjusts Editas Medicine Price Target to $7 From $10, Maintains Sector Perform - Speculative Risk Rating ... Stock Editas Medicine, Inc. - Nasdaq . Consensus Editas Medicine, Inc. CATEGORIES. Indexes; …The three major U.S. stock exchanges are the New York Stock Exchange (NYSE), the NASDAQ and the American Stock Exchange (AMEX). As of 2014, the NYSE is the largest and most prestigious of the three. The NASDAQ is a virtual stock exchange.

Investing in the stock market takes a lot of courage, a lot of research, and a lot of wisdom. One of the most important steps is understanding how a stock has performed in the past. Of course, the past is not a guarantee of future performan...The Editas Medicine, Inc stock price fell by -0.754% on the last day (Thursday, 30th Nov 2023) from $10.61 to $10.53. During the last trading day the stock fluctuated 5.51% from a day low at $10.44 to a day high of $11.01. The price has risen in 6 of the last 10 days and is up by 19.12% over the past 2 weeks.Track Editas Medicine Inc (EDIT) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsBased on short-term price targets offered by 13 analysts, the average price target for Editas Medicine comes to $13.85. The forecasts range from a low of $7.00 to a high of $30.00. The average ...Funding, Valuation & Revenue. Editas Medicine has raised $163M over 5 rounds. Editas Medicine's latest funding round was a IPO for $94.4M on February 3, 2016. Editas Medicine's valuation in August 2015 was $315.85M. Editas Medicine's latest post-money valuation is from February 2016.Oct 15, 2020 · The Editas Medicine stock forecast is 21.770642845038 USD for 2024 November 30, Saturday; and 92.327 USD for 2028 November 30, Thursday with technical analysis. Editas Medicine (EDIT) stock price prediction is 21.770642845038 USD. Gene editing stocks rallied Thursday as Wall Street took notice of the underperforming subsector issuing a series of bullish views despite recent selloff. Read more here.

With stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.

Editas Medicine Inc. Watch NEW Set a price target alert After Hours Last Updated: Dec 1, 2023 7:55 p.m. EST Delayed quote $ 10.73 -0.04 -0.37% After Hours Volume: 26.03K Advanced Charting...Real-time Price Updates for Editas Medicine (EDIT-Q), along with buy or sell indicators, analysis, charts, historical performance, news and moreWhat was the 52-week low for Editas Medicine stock? The low in the last 52 weeks of Editas Medicine stock was 6.08. According to the current price, Editas Medicine is 174.67% away from the 52-week ... Price is a widely used stock evaluation measure. Find the latest Price for Editas Medicine (EDIT) ... Editas Medicine (EDIT) Reports Q3 Loss, Tops Revenue Estimates 11/03/23-7:45AM EST ZacksEditas Medicine stock price target cut to $35 from $80 at Truist Nov. 18, 2022 at 7:08 a.m. ET by Tomi Kilgore Editas Medicine started at neutral with $18 stock price target at …11 Ago 2021 ... The stock price of Editas Medicine, a biotechnology company focused on developing treatments using gene editing technology, has seen a rise ...Over the past year, shares of gene-editing companies Editas Medicine ( EDIT -0.23%) and CRISPR Therapeutics ( CRSP 6.42%) have shot up 129% and 212%, respectively. Their mouth-watering returns ...Editas Medicine (EDIT) stock climbs 12% on Friday and 7% in the pre-market hours today, after the company beat estimates for both earnings and revenues in first-quarter 2023. Pipeline progress in ...Establishing ownership of stock depends on how the stock was purchased, according to the Securities and Exchange Commission. A brokerage firm may have purchased the stock or it may have been bought directly from the company.Price is a widely used stock evaluation measure. Find the latest Price for Editas Medicine (EDIT) ... Editas Medicine (EDIT) Reports Q3 Loss, Tops Revenue Estimates 11/03/23-7:45AM EST Zacks

All three healthcare stocks are showing solid long-term potential. ... Editas Medicine is focusing on a gene therapy EDIT-301 for rare blood disorders. ... Price as of November 30, 2023, 4:00 p.m ...

The Editas Medicine, Inc stock price fell by -0.754% on the last day (Thursday, 30th Nov 2023) from $10.61 to $10.53.During the last trading day the stock fluctuated 5.51% from a day low at $10.44 to a day high of $11.01.The price has risen in 6 of the last 10 days and is up by 19.12% over the past 2 weeks. Volume has increased on …

Real-time Price Updates for Editas Medicine (EDIT-Q), along with buy or sell indicators, analysis, charts, historical performance, news and moreInvesting in the stock market takes a lot of courage, a lot of research, and a lot of wisdom. One of the most important steps is understanding how a stock has performed in the past. Of course, the past is not a guarantee of future performan...Editas Medicine is forecast to grow earnings and revenue by 0.04% and 51.7% per annum respectively. EPS is expected to grow by 13.5% per annum. Return on equity is forecast to be -133.7% in 3 years.Aug 23, 2023 · The average price targets for Editas Medicine and Intellia Therapeutics are $13.18 and $83.75, respectively, according to Yahoo! Finance. That implies an upside of about 54% for the former and 119 ... The Editas Medicine stock forecast is 21.770642845038 USD for 2024 November 30, Saturday; and 92.327 USD for 2028 November 30, Thursday with technical analysis. Editas Medicine (EDIT) stock price prediction is 21.770642845038 USD.Editas Medicine stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics Motley Fool - Mon Oct 2, 9:00AM CDT . The better of the pair should be able to beat Bluebird Bio. EDIT: 10.77 (+2.28%) CRSP: 68.65 (+2.88%) Why Editas …Get the latest Editas Medicine, Inc. (EDIT) stock news and headlines to help you in your trading and investing decisions.Editas Medicine, Inc. analysts consensus, targets, ratings and recommendations | Nasdaq: EDIT | Nasdaq ... RBC Capital Adjusts Editas Medicine Price Target to $7 From $10, Maintains Sector Perform - Speculative Risk Rating ... Stock Editas Medicine, Inc. - Nasdaq . Consensus Editas Medicine, Inc. CATEGORIES. Indexes; …

What happened. Shares of Editas Medicine ( EDIT 2.28%) were up 13.9% this week as of the market close on Thursday. Most of this big gain came after a key announcement from the company on Wednesday ...Find out the current price target and stock forecast for Editas Medicine ... Based on short-term price targets offered by 13 analysts, the average price target for Editas Medicine comes to $13.85 ...Consider, for instance, Editas Medicine (EDIT-6.20%) ... Stock Advisor list price is $199 per year. Join Stock Advisor Cumulative Growth of a $10,000 Investment in Stock Advisor.Instagram:https://instagram. best mortgage banks in njatsg incstock projectionswhere are oil prices headed Find the latest Editas Medicine, Inc. (EDIT) stock quote, history, news and other vital information to help you with your stock trading and investing.Editas Medicine stock declined 13% over a 5-day trading period ending 1/21/2021, compared to broader market (S&P500) rise of 1.3%. A change of -13% or more over 5 trading days is a 6% likelihood ... where to buy gold cheaphighest return reits Find out the direct holders, institutional holders and mutual fund holders for Editas Medicine, Inc. (EDIT). kraft stock dividend Editas Medicine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023. Nov. 03. CI. North American Morning Briefing : S&P 500 Futures -2-. Nov. 03. DJ. Editas Medicine, Inc. to Present Clinical Data from the Rubber and Edithal Trials of Edit-301 At the Ash 2023 Annual Meeting and in A Company-Sponsored ...DraftKings (NASDAQ:DKNG) was upgraded to Buy from Neutral at MoffettNathanson, with its price target raised by $6.00 to $37.00. Find the latest Editas Medicine, Inc. (EDIT) stock quote, history, news and other vital information to …